November | 2012 | GlobeImmune

GI-5005 Improves Virologic Clearance of HCV in Combination with PegIFN/Ribavirin in IL28B T/T Patients

November 11, 2012

Clinical Trial Data to be Presented at The Liver Meeting® 2012 in Boston BOSTON, Nov. 11, 2012 – GlobeImmune, Inc., today announced Phase 2b clinical data showing that GI-5005, a Tarmogen® product candidate for the treatment of chronic hepatitis C … Continue reading →

GI-13020 Tarmogen® for the Treatment of Chronic Hepatitis B Generates Antigen-specific T Cell Responses in Key Preclinical Studies

November 10, 2012

Data to be Presented Today at The Liver Meeting® 2012 in Boston BOSTON, Nov. 10, 2012 – GlobeImmune, Inc. today announced that GI-13020, an investigational therapeutic vaccine designed using the company’s proprietary Tarmogen® product platform for the treatment of chronic … Continue reading →